LeMaitre Vascular Inc (NASDAQ:LMAT) – Stock analysts at First Analysis issued their Q4 2018 earnings estimates for shares of LeMaitre Vascular in a report released on Friday. First Analysis analyst forecasts that the medical instruments supplier will post earnings of $0.28 per share for the quarter. First Analysis also issued estimates for LeMaitre Vascular’s FY2019 earnings at $1.13 EPS.
LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.01. The company had revenue of $26.15 million during the quarter, compared to the consensus estimate of $26.23 million. LeMaitre Vascular had a return on equity of 16.93% and a net margin of 17.03%. LeMaitre Vascular’s revenue was up 12.3% on a year-over-year basis. During the same period last year, the company earned $0.13 earnings per share.
A number of other analysts also recently issued reports on the company. BidaskClub upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Friday, March 9th. Zacks Investment Research upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a research report on Wednesday, February 28th. Finally, Canaccord Genuity restated a “hold” rating and issued a $33.00 price target on shares of LeMaitre Vascular in a research report on Friday, February 23rd. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $34.00.
Shares of LeMaitre Vascular (NASDAQ:LMAT) traded down $0.13 on Monday, reaching $36.83. The company had a trading volume of 36,080 shares, compared to its average volume of 123,477. The company has a market capitalization of $715.14, a P/E ratio of 43.48, a PEG ratio of 2.53 and a beta of 0.55. LeMaitre Vascular has a 12 month low of $22.95 and a 12 month high of $39.88.
Several large investors have recently added to or reduced their stakes in LMAT. Victory Capital Management Inc. lifted its position in shares of LeMaitre Vascular by 181.2% during the third quarter. Victory Capital Management Inc. now owns 4,139 shares of the medical instruments supplier’s stock worth $155,000 after purchasing an additional 2,667 shares during the last quarter. Royal Bank of Canada lifted its position in shares of LeMaitre Vascular by 856.5% during the second quarter. Royal Bank of Canada now owns 5,031 shares of the medical instruments supplier’s stock worth $157,000 after purchasing an additional 4,505 shares during the last quarter. BB&T Corp bought a new stake in shares of LeMaitre Vascular during the fourth quarter worth $202,000. Voya Investment Management LLC bought a new stake in shares of LeMaitre Vascular during the second quarter worth $203,000. Finally, Advisor Group Inc. lifted its position in shares of LeMaitre Vascular by 119.1% during the third quarter. Advisor Group Inc. now owns 5,483 shares of the medical instruments supplier’s stock worth $205,000 after purchasing an additional 2,980 shares during the last quarter. Institutional investors and hedge funds own 72.88% of the company’s stock.
In other news, Chairman George W. Lemaitre sold 30,000 shares of LeMaitre Vascular stock in a transaction on Wednesday, March 7th. The stock was sold at an average price of $36.19, for a total transaction of $1,085,700.00. Following the completion of the sale, the chairman now directly owns 3,180,709 shares in the company, valued at $115,109,858.71. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO George W. Lemaitre sold 5,700 shares of LeMaitre Vascular stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $35.56, for a total value of $202,692.00. Following the sale, the chief executive officer now owns 3,259,263 shares of the company’s stock, valued at $115,899,392.28. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 137,736 shares of company stock valued at $4,866,186. 23.70% of the stock is owned by corporate insiders.
The business also recently declared a quarterly dividend, which will be paid on Thursday, April 5th. Investors of record on Thursday, March 22nd will be given a $0.07 dividend. The ex-dividend date of this dividend is Wednesday, March 21st. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.06. This represents a $0.28 dividend on an annualized basis and a yield of 0.76%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 25.88%.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.